Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018

Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Euro surveillance : bulletin européen sur les maladies transmissibles 2018-02, Vol.23 (5), p.2
Hauptverfasser:	Skowronski, Danuta M, Chambers, Catharine, De Serres, Gaston, Dickinson, James A, Winter, Anne-Luise, Hickman, Rebecca, Chan, Tracy, Jassem, Agatha N, Drews, Steven J, Charest, Hugues, Gubbay, Jonathan B, Bastien, Nathalie, Li, Yan, Krajden, Mel
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antigens Canada - epidemiology Case-Control Studies Child Epidemics Female Humans Influenza Influenza A Virus, H3N2 Subtype - classification Influenza A Virus, H3N2 Subtype - genetics Influenza A Virus, H3N2 Subtype - immunology Influenza B virus - classification Influenza B virus - genetics Influenza B virus - immunology Influenza Vaccines - immunology Influenza, Human - epidemiology Influenza, Human - immunology Influenza, Human - prevention & control Influenza, Human - virology Male Middle Aged Rapid Communication Seasons Sentinel Surveillance Vaccination - statistics & numerical data Vaccine Potency Vaccines Viruses Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was low at 17% (95% confidence interval (CI): -14 to 40). Adjusted VE for influenza B was higher at 55% (95% CI: 38 to 68) despite prominent use of trivalent vaccine containing lineage-mismatched influenza B(Victoria) antigen, suggesting cross-lineage protection.
ISSN:	1560-7917 1025-496X 1560-7917
DOI:	10.2807/1560-7917.ES.2018.23.5.18-00035